Zobrazeno 1 - 10
of 319
pro vyhledávání: '"Santiago Viteri"'
Autor:
Ana Giménez‐Capitán, Estela Sánchez‐Herrero, Lucía Robado de Lope, Andrés Aguilar‐Hernández, Ivana Sullivan, Virginia Calvo, Irene Moya‐Horno, Santiago Viteri, Carlos Cabrera, Cristina Aguado, Noelia Armiger, Joselyn Valarezo, Clara Mayo‐de‐las‐Casas, Noemí Reguart, Rafael Rosell, Mariano Provencio, Atocha Romero, Miguel A. Molina‐Vila
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1884-1897 (2023)
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material
Externí odkaz:
https://doaj.org/article/895f32ea609d4f95922800c025292cd9
Autor:
Ruth Román-Lladó, Cristina Aguado, Núria Jordana-Ariza, Jaume Roca-Arias, Sonia Rodríguez, Erika Aldeguer, Mónica Garzón-Ibañez, Beatriz García-Peláez, Marta Vives-Usano, Ana Giménez-Capitán, Andrés Aguilar, Alejandro Martinez-Bueno, María Gonzalez Cao, Florencia García-Casabal, Santiago Viteri, Clara Mayo de las Casas, Rafael Rosell, Miguel Angel Molina-Vila
Publikováno v:
Journal of Molecular Pathology, Vol 4, Iss 1, Pp 57-68 (2023)
Genetic and drug sensitivity assays on primary cultures are not only of basic but also of translational interest and could eventually aid oncologists in the selection of treatments. However, cancer cells need to be identified and differentiated from
Externí odkaz:
https://doaj.org/article/4aa6f599da1a468abb18119b19ad755f
Autor:
Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai‐Hong Ignatius Ou, Joshua M. Bauml, Scott A. Shell, Michael Schaffer, Junchen Gu, Jennifer B. Rose, Joshua C. Curtin, Parthiv Mahadevia, Nicolas Girard
Publikováno v:
Molecular Oncology, Vol 17, Iss 2, Pp 230-237 (2023)
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets to determine the frequency of ex20ins variants, and the ability of po
Externí odkaz:
https://doaj.org/article/c4da93c6b1ad420a85fa00e6dd68825d
Autor:
Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Sylvia Vetrhus, Alex Martinez-Marti, Santiago Viteri, Alejandro Navarro, Jon Zugazagoitia, Santiago Ponce, Mercedes Herrera-Juarez, Mathieu Lederlin, Thomas Birkballe Hansen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleura
Externí odkaz:
https://doaj.org/article/948af889fc44483eac5e19bcc3f77280
Autor:
Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria, Rafael Rosell
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/907f95952a6f451dab4695071025b8b3
Autor:
Marta Vives-Usano, Beatriz García Pelaez, Ruth Román Lladó, Mónica Garzón Ibañez, Erika Aldeguer, Sonia Rodriguez, Andrés Aguilar, Francesc Pons, Santiago Viteri, Carlos Cabrera, Maria José Catalán, Irene Moya, María Gonzalez Cao, Juan José García-Mosquera, Alejandro Martinez-Bueno, Ekaterina Meshoulam, Nuria Jordana, Laura Berrocal, Rafael Rosell, Miguel Angel Molina, Clara Mayo de las Casas
Publikováno v:
Journal of Molecular Pathology, Vol 2, Iss 2, Pp 123-134 (2021)
Somatic copy number variations (CNV; i.e., amplifications and deletions) have been implicated in the origin and development of multiple cancers and some of these aberrations are designated targets for therapies. Although FISH is still considered the
Externí odkaz:
https://doaj.org/article/ca772e98c22442f8b9bdad5c2f30d92d
Autor:
Daniel Castellano, Andrea B. Apolo, Camillo Porta, Jaume Capdevila, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Pablo Maroto
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a syste
Externí odkaz:
https://doaj.org/article/3a9dbb257b134acc968d6ee7d8d17ca9
Autor:
Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Daniel Castellano
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Cabozantinib is approved, in various settings, for the treatment of renal cell carcinoma, medullary thyroid cancer, and hepatocellular carcinoma, and it has been investigated for the treatment of other cancers. With the available evidence
Externí odkaz:
https://doaj.org/article/2051059e7aad49d3b982e6644fb0878a
Autor:
Cristina Aguado, Cristina Teixido, Ruth Román, Roxana Reyes, Ana Giménez‐Capitán, Elba Marin, Carlos Cabrera, Nuria Viñolas, Sergi Castillo, Silvia Muñoz, Ainara Arcocha, Laura López‐Vilaró, Ivana Sullivan, Erika Aldeguer, Sonia Rodríguez, Irene Moya, Santiago Viteri, Andrés Felipe Cardona, Ramon Palmero, Cristina Sainz, Miguel Mesa‐Guzmán, Maria D. Lozano, Andrés Aguilar‐Hernández, Alejandro Martínez‐Bueno, María González‐Cao, Elena Gonzalvo, William P. J. Leenders, Rafael Rosell, Luis M. Montuenga, Aleix Prat, Miguel A. Molina‐Vila, Noemi Reguart
Publikováno v:
Molecular Oncology, Vol 15, Iss 2, Pp 350-363 (2021)
MET inhibitors have shown activity in non‐small‐cell lung cancer patients (NSCLC) with MET amplification and exon 14 skipping (METΔex14). However, patient stratification is imperfect, and thus, response rates have varied widely. Here, we studied
Externí odkaz:
https://doaj.org/article/5db041644f0248ee90bd178c373b1867
Autor:
Atocha Romero, Eloisa Jantus‐Lewintre, Beatriz García‐Peláez, Ana Royuela, Amelia Insa, Patricia Cruz, Ana Collazo, Javier Pérez Altozano, Oscar Juan Vidal, Pilar Diz, Manuel Cobo, Berta Hernández, Sergio Vázquez Estevez, Gretel Benítez, Maria Guirado, Margarita Majem, Reyes Bernabé, Ana Laura Ortega, Ana Blasco, Joaquim Bosch‐Barrera, Jose M. Jurado, Jorge García González, Santiago Viteri, Carlos Garcia Giron, Bartomeu Massutí, Ana Lopez Martín, Alejandro Rodriguez‐Festa, Silvia Calabuig‐Fariñas, Miguel Ángel Molina‐Vila, Mariano Provencio
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 43-56 (2021)
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven methodolo
Externí odkaz:
https://doaj.org/article/fee84be40c92476693b579001138154a